Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1397Neoplasms 1129Prostatic Neoplasms 744Lung Neoplasms 619Colorectal Neoplasms 596Carcinoma, Non-Small-Cell Lung 569Carcinoma, Hepatocellular 413Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 355Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 309Head and Neck Neoplasms 289Neoplasm Metastasis 273Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 253Uterine Cervical Neoplasms 248Recurrence 248Melanoma 242Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 213Sarcoma 207Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 183

Interventions

pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nephroureterectomy 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Renal Pelvis and Ureter Urothelial Carcinoma × Clear all
NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Recruiting
21 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡